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ABSTRACT 
 
Background: Alteration in peripheral blood lymphocytes (PBLs) is usually investigated 
to provide an evidence of the host immune responses to tumor antigens. The tumor 
infiltrating NK cells interact most closely with the tumor cells and more accurately 
reflect tumor host interactions. Objective: To analyze peripheral blood and tumor 
associated Natural Killer (NK) cells in patients with breast cancer by immunopheno-
typing. Methods: Twenty women suffering from breast cancer were examined; 12 of 
them were confirmed histologically to be invasive ductal carcinoma. PBL and tissue 
samples from patients and matched control group were processed for analysis by 
flow cytometry. Results: Results of PBL analysis indicated a significant (P<0.05) 
increase in both the total number and activated NK cells in invasive ducal carcinoma 
patients compared to normal controls. No significant differences were noticed in the 
percent of NK cells and their activation marker expression in intra tumor lesion of the 
invasive ductal carcinoma and other tumors compared to benign lesions, however a 
decrease in the total NK number and activated NK cells was observed with progression 
of the tumor. Conclusion: Data of this investigation conclude that the total and 
activated NK cell number increase in peripheral blood of patients with breast cancer. 
The relationship between peripheral blood and intratumor NK cells needs more 
clarification, however, a decrease in intratumor NK cell number and their activation 
status occurs with tumor progression. 
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INTRODUCTION 
 
Invasive ductal carcinoma is the most common type of breast cancer in Iran. The 
immune system is capable of responding to cancer as evidenced by systemic, 
regional, and intratumoral leukocyte activation. For individual patients there is no 
predictable relationship between leukocyte composition, or function, and the prognosis 
of the disease (1). 
Infiltrated leukocytes to neoplastic tissues are a target for therapeutic intervention 
(2). These cells are endowed with tumor destructive features, exerted directly on 
neoplastic cells or via soluble mediators which affect components of the tumor tissue 
(3). Although T cells are the most tumor infiltrating immune cells (4), the activity 
status of different cytotoxic leukocytes (mononuclear, phagocytic and NK cells) 
encompasses tumor cells resistant to chemotherapeutic agents (2). 
Impaired immune responses occur frequently in cancer patients, but the mechanism 
of the induced immune defects remains poorly understood (5). In clinical practice, 
reports have been made on immunosuppression even after surgical excision of 
primary tumor or at relapse. However, the relationship between undefined or overt 
metastasis and the host immune system has been sufficiently examined over a 
prolonged period (6). 
It has been noted that the tumor host relationship and cell mediated immunity in the 
PBL does not often correlate with prognosis (7). 
 
 
MATERIALS AND METHODS 
 
Sampling 
Twenty patients who underwent surgical procedure in Institute of Cancer of 
Imam-Khomeini Hospital, Tehran were studied. The age of patients ranged from 25-
65 (mean 45.4) years. The surgical procedure undergone was radial mastectomy. 
Twelve of the patients were diagnosed histologically to be invasive ductal carcinoma 
(IDC) (60%), two of the patients were invasive lobular carcinoma (ILC) (10%), one 
patient was intra ductal carcinoma (IDCC), one patient was atypic medullary carci-
noma (AMC) and one patient was fibrocystic. Three patients had benign tumors that 
were considered as a separate group. From each patient one centimeter tumor tissue 
(biopsies) was obtained. PBL of 10 matched control women (group1) and 8 cancer 
patients (4 IDC as group 2 and 4 other types of tumor as group3) were collected in 
EDTA-coated tubes prior to any chemoradiotherapy. The mononuclear cell fraction 
of blood samples were isolated by ficoll and processed for immunostaining (see below). 
The patients and control groups participated in this study after informed consent. 
Preparation of Tumor Cell Suspension 
Biopsies of human solid tumor were cut into small pieces with forceps and scalpel. 
The pieces were rinsed twice with phosphate buffer saline, then 5ml of cocktail 
enzymes (0.05 mg/ml collagenase and 0.002 mg/ml DNase) were added and the 
mixture was placed in 37oC incubator for 2-4 hrs. The suspensions were passed 
through 150-micron stainless steel mesh. Cell were washed twice and labeled with 
monoclonal antibodies. 
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Immunophenotyping  
The following fluorescent monoclonal antibodies (mAb) (DAKO, Denmark) were 
used to identify leukocytes and NK cells in both PBL and tumor cell suspensions: 
anti–CD45+  for detection of  leukocytes; anti-CD45+/CD56+ for detection of  NK 
cells and anti- CD56+/CD25+ for detection of activated NK cells. 
 We established the reference immunophenotypic pattern using standard procedures. 
In this study 100μl of each blood/tissue samples was immunostained with 10μl mAbs 
directly conjugated with Fluorescein Isothiocyanate (FITC) or R-Phycoerythrin 
(RPE) in Q-Prep apparatus, then, three immunopreps were added automatically, 0.7 
ml immunoprep A (Formic Acid 1.2ml/L), 0.32ml immunoprep B (Sodium Carbonate 
6.0g/L, Sodium Chloride 14.5 g/L, Sodium Sulfate 31.3 g/L) and 0.14 ml immunoprep 
C (Paraformaldehyde 10.0 g/L, Phosphate Buffer). Each sample was then kept at 2-8 
oC in the dark before analyzing in 24 hrs (8).  
Flowcytometric Analysis 
Cell samples were measured on a coulter flowcytometer with serial filter configuration. 
The analysis was focused on the myeloid areas of the forward and side scatters. 
Double stained cells were analyzed using coulter software. 
Statistics 
In this study one-way analysis of variance (ANOVA) and Kruskal-Wallis nonparametric 
test were employed using SPSS software. 
 
 
RESULTS 
 
PBL Natural Killer Cells in Patients and Controls 
In order to estimate the percent of leukocyte (CD45+cells) and NK cells 
(CD45+CD56+ cells) in the PBL of patients suffering from breast cancer, the protocol 
shown in table 1 was employed. Results of PBL indicated a significant (P<0.05) 
increase in the total NK cell percent in invasive ductal carcinoma compared to normal 
group. Whereas a significant (P<0.05) decrease was observed in other tumors (other 
than invasive ductal carcinoma) compared to normal group (Table1).  
In the case of activated NK cells (CD56+ CD25+ cells ) results indicated that the 
mean percent of CD56+ CD25+ cells  in the PBL of both invasive ductal carcinoma 
and other breast tumors were significantly (P<0.05) increased compared to the normal 
group (Table1). 
Percentage of Tumor Associated NK Cells 
The results of intratumor NK cells are summarized in table2. No significant differences 
were noticed in the percent of NK cells in intratumor lesion of the invasive ductal 
carcinoma and other tumors compared to benign ones. 
In order to detect the activated tumor associated NK cells, anti-CD25 mAb was used. 
Results indicated no significant difference between patients with malignant and those 
with benign tumors. 
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Table 1. The percentage of the total and activated NK cells in the peripheral 
blood of the breast cancer patients and normal groupa 
 
% % % % % 
Subject 
No. 
of cases CD45+ CD45+ CD56+ CD45+ 
CD56+/CD45+ 
CD56+ 
CD25+ 
CD56+ 
CD25+/CD56+ 
Group 1 
Normal 10 85.4 2.4 2.8 0.1 4.1 
Group 2 
IDC Patient 4 79.4 2.97
b 3.7b 1.55 b 52.1 
Group 3 
ILC+AMC+IDCC 
Patients 
4 89.8 1.67b 1.8 b 0.3 b 17.9 b 
a analysis was done in  Lymphocyte gate 
b. indicate a significant difference in comparison with normal group1 (P<0.05) 
IDC: invasive ductal carcinoma, ILC: invasive lobular carcinoma 
AMC: atypic medullary carcinoma, IDCC: intra ductal carcinoma 
 
 
Table 2. Immunostatus of tumor associated NK cells in breast cancer patientsa 
 
% % % % % 
CD56+  
CD25+/CD56+  
CD56+ CD25+ CD45+ 
CD56+/CD45+ 
CD45+ CD56+ CD45+ 
No. 
of cases subjects 
62 1.35 14.8 2.18 14.7 12 Group 1 IDC Patient 
64 1.54 15 2.4 16 5 
Group 2 
ILC+AMC+IDCC 
Patients 
65.2 1.5 13.1 2.3 17.5 3 Group 3 Benign breast tumor 
a the analysis was done as ungated and results were not significant 
IDC: invasive ductal carcinoma, ILC: invasive lobular carcinoma 
AMC: atypic medullary carcinoma, IDCC: intra ductal carcinoma 
 
Correlation between Intratumor NK Cells and Clinical Tumor Staging  
In order to assess the correlation between the intratumor total and activated NK cells 
with different stages of tumor, patients with stages 1, 2, 3 and 4 were evaluated. Re 
sults in figure 1 indicate a significant (P<0.05) decrease in both total number and the 
activated NK cells at the tumor site in stages 3 and 4 compared to stage 1. 
 
 
Figure1. Correlation between intratumor NK cells and stages of tumor 
Correlation between intratumor NK cells and stages of tumor 
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DISCUSSION 
 
The great majority of tumors infiltrating lymphocytes (TILs) are CD3+ T cells. NK 
cells and B lymphocytes are usually very few in neoplastic tissues (4, 9). At least in 
some immunogenic tumors, TILs contain a higher proportion of tumor specific 
effecter lymphocytes in comparison to peripheral blood lymphocytes (PBLs). Tumor 
antigen recognition by TILs is manifested by tumor killing or cytokine production 
(10, 11). 
Interleukin-12 (IL-12) has potent antitumor activities via NK and cytotoxic T cells. 
However, the underlying molecular mechanisms are poorly understood. Shi X and 
coworkers reported the genome-wide analysis of gene expression in a primary 
murine mammary carcinoma model that resembles human breast cancer, following 
the therapeutic application of recombinant IL-12, which restricted tumor growth and 
metastasis (19). IL-12 was able to curtail neovascularization in the tumor as well as 
enhance the number of tumor-infiltrating lymphocytes (20). 
In this investigation we found that the peripheral blood NK cell number of patients 
with IDC and activated NK cells from patients with IDC or other tumor types were 
significantly increased compared to the normal group (Table1). In concordance with 
this study Murta et al. reported that patients with advanced breast cancer showed 
increases in B and NK cells in PBLs (20). 
Despite of these differences in peripheral blood, no differences were observed in 
total intratumor NK and activated NK cells when patients with malignant tumors 
were compared with those with benign ones. Some investigators have believed that 
PBL natural killer cells do not reflect the tumor host relationship and cell mediated 
immunity in the PBL does not often correlate with prognosis (7, 22). Functional 
analysis of TILs and PBLs have been also indicated that cellular immunity is down 
regulated at the site of tumor whereas cytotoxic immune response as a part of cellular 
immunity predominates in peripheral blood. (21). 
We found a significant negative correlation between the both the total number and 
activated NK cells and the stage of tumor (Fig.1). This finding is in agreement with 
previous reports on murine models which reported that NK cells infiltrate the lesions 
of tumor at a very early stage (13). Other studies have also indicated a low percent of 
NK cells in the intratumor infiltration (13, 14) and NK cells presence isolated from 
the infiltrate (4). Kuroda et al. found that the medulary carcinoma of the breast contained 
very few NK cells (15). In contrary to our findings, however, Vgenopoulou et al. 
showed that high-grade carcinomas exhibited higher numbers of endotumoral NK 
cells and B-cell aggregates (16). 
Recently, we reported that TAMs and PBL mononuclear cells were not different in 
breast cancer patients and the control group (23), but here our results indicated that 
the total number and the activation marker expression of PBL Natural Killer cells 
significantly increased, at least, in IDC type of breast cancer while the total number 
and activation marker of these cells decreased with tumor progression. Additional 
studies concerning the tumor infiltrating T, B and NK cells are required to clarify 
further relationship between these cells in the breast cancer and also their cytolytic 
function against tumor cells. 
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